Indeed, although CPHPC treatment very substantially reduces the amount of SAP in systemic amyloid deposits, the affinity of binding of SAP to CPHPC is not sufficient for the drug to strip all SAP from its avid multivalent binding to the very abundant amyloid deposits that are present in these patients [29]. This evidence concerns the gene APCS and amyloidosis.